Hudson Bay Capital Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Hudson Bay Capital Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-87,759	Closed	-$408K	–	1399
2021 Q4	$408K	Buy	+87,759	New	+$545K	﹤0.01%	868
2020 Q3	–	Sell	-180,000	Closed	-$1.13M	–	664
2020 Q2	$1.13M	Buy	+180,000	New	+$689K	0.02%	374
2019 Q3	–	Sell	-662,059	Closed	-$1.77M	–	498
2019 Q2	$1.77M	Buy	+662,059	New	+$2.38M	0.04%	288

Other funds holding SRNE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Hudson Bay Capital Management's SRNE Position: Q1 2022 in Review

Hudson Bay Capital Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2022, closing a stake of 87,759 shares — an estimated $408K sold.

Hudson Bay Capital Management first reported a position in SRNE in Q2 2019 and held it in 3 quarters. The position peaked at $1.77M in Q2 2019. 235 funds tracked by Wall St. Rank hold SRNE as of Q1 2022.

Hudson Bay Capital Management reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
Hudson Bay Capital Management sold 87,759 Sorrento Therapeutics, Inc. shares in Q1 2022, an estimated $408K.
Hudson Bay Capital Management first reported a position in Sorrento Therapeutics, Inc. in Q2 2019 and held it in 3 quarters.
Hudson Bay Capital Management's Sorrento Therapeutics, Inc. position peaked at $1.77M in Q2 2019.
235 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2022.

Based on Hudson Bay Capital Management's 13F filing for Q1 2022, filed 16 May 2022.